Derisking and accelerating oral peptide delivery via novel computational drug development tools

Continued innovation is critical to successfully formulate and advance complex moieties. MDS models can aid in the rapid development of bioavailability challenged molecules, including helping to design lipid-based formulations that are appropriate for peptide molecules. As the drug development pipeline continues to consist of more and more low-bioavailability molecules, computational tools may be a powerful implement for drug developers to advance candidate molecules. Contract development and manufacturing organisations (CDMOs) can use MDS tools to help biopharma companies enhance molecule bioavailability and rapidly move new medicines forward into clinical trials and to market. © 2020 HPCi Media LTD. All rights reserved.